Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Immunotherapy Vaccine and Herceptin in Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03014076
Recruitment Status : Completed
First Posted : January 9, 2017
Last Update Posted : January 9, 2017
Sponsor:
Information provided by (Responsible Party):
George E. Peoples, Cancer Insight, LLC

Brief Summary:

The purpose of this trial is to determine if combination immunotherapy with HER2/neu GP2 peptide + GM-CSF vaccine and trastuzumab is safe and immunologically effective in treatment of patients with HER2/neu over-expressing breast cancer in the adjuvant setting. While not a primary endpoint, time to recurrence is measured for enrolled subjects. The objectives of the study are the following:

  • Assess safety and document local and systemic toxicity to combination immunotherapy with GP2 peptide + GM-CSF vaccine and trastuzumab
  • Evaluate the in vitro and in vivo immunologic responses to combination immunotherapy of GP2 peptide + GM-CSF vaccine and trastuzumab
  • Determine maximum tolerated dose and optimal biologic dose for the combination immunotherapy of GP2 peptide + GM-CSF vaccine and trastuzumab

Condition or disease Intervention/treatment Phase
Breastcancer Drug: GP2 peptide + GM-CSF vaccine plus trastuzumab Drug: Trastuzumab Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase Ib Trial of Combination Immunotherapy With HER2/Neu Peptide GP2 + GM-CSF Vaccine and Trastuzumab in Breast Cancer Patients
Study Start Date : January 2008
Actual Primary Completion Date : January 2016
Actual Study Completion Date : January 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer
Drug Information available for: Trastuzumab

Arm Intervention/treatment
Experimental: GP2 peptide + GM-CSF + trastuzumab
HLA-A2+/A3+ subjects receive GP2 + GM-CSF vaccine and trastzumab
Drug: GP2 peptide + GM-CSF vaccine plus trastuzumab
HLA-A2+/A3+ subjects are given the GP2 peptide vaccine plus trastuzumab

Active Comparator: Trastuzumab
HLA-A2-/A3- subjects followed as controls receiving trastuzumab.
Drug: Trastuzumab
HLA-A2-/A3- patients are followed as controls receiving trastuzumab only.
Other Name: Herceptin




Primary Outcome Measures :
  1. Treatment-Related Adverse Events as Assessed by CTCAE v4.0 [ Time Frame: 12 months ]
    Patients receiving treatment will be followed from baseline to completion of study for adverse events using CTCAE v4.0



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Age > 18 years
  • HER2/neu+ over-expressing breast cancer (IHC 3+ or FISH ≥2.0)
  • Patients who are receiving adjuvant trastuzumab as standard of care treatment
  • Completion of breast cancer therapy (i.e., surgery, radiation, and chemotherapy as appropriate per standard of care for patients' specific cancer) to exclude trastuzumab (Patients on oral hormonal therapy as part of their adjuvant breast cancer treatment will be maintained on their regimens.)
  • Enrollment must occur so that patients' trastuzumab treatment and vaccine schedule overlap for all 6 vaccinations and so that first vaccination occurs after a standard of care Multiple Gated Acquisition Scan (MUGA)
  • ECOG performance status (PS) 0-1
  • Clinically cancer-free (no evidence of disease; excluding +CTC)
  • If the patient is of childbearing potential, she must be willing to practice adequate contraception through the study treatment period and for 2 months after completion of the injection sites
  • Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

  • Clinical and/or radiographic evidence of residual or persistent breast cancer
  • Receiving immunosuppressive therapy to include methotrexate or steroids (note: the use of prednisone, or equivalent, <2.0mg/day, is allowed)
  • Tbili >1.8, creatinin >2, hemoglobin <10, platelets <100,000/mm³, WBC <2,000
  • Active pulmonary disease requiring medication to include multiple inhalers
  • Patients may not be receiving any other investigational agents (except with permission of the Lead Principal Investigator)
  • Pregnant or are nursing
  • History of autoimmune disease (patients with vitiligo not excluded)
  • HIV positive
  • Previous or concomitant malignancies at other sites, except effectively treated non- melanoma skin cancers or carcinoma in situ of the cervix or effectively treated malignancy that has been in remission for over 5 years and highly likely to have been cured
  • Other concurrent severe medical problems, unrelated to the malignancy, that would significantly limit full compliance with the study or expose the patient to unacceptable risk
  • Uncontrolled congestive heart failure or hypertension, unstable heart disease (coronary artery disease or myocardial infarction) or uncontrolled arrhythmia at the time of enrollment
  • Psychiatric, addictive, or any disorder which compromises ability to give truly informed consent for participation in this study or adequate compliance

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03014076


Sponsors and Collaborators
Cancer Insight, LLC
Investigators
Layout table for investigator information
Principal Investigator: George E Peoples, MD Cancer Insight

Layout table for additonal information
Responsible Party: George E. Peoples, CEO/Founder, Cancer Insight, LLC
ClinicalTrials.gov Identifier: NCT03014076     History of Changes
Other Study ID Numbers: C.2008.146
First Posted: January 9, 2017    Key Record Dates
Last Update Posted: January 9, 2017
Last Verified: January 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Vaccines
Sargramostim
Trastuzumab
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents, Immunological
Antineoplastic Agents